As filed with the Securities and Exchange Commission on May 7, 2021

Registration No. 333-

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

 

Aclaris Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)

 

     
Delaware   46-0571712
(State or other jurisdiction of Incorporation or organization)   (I.R.S. Employer Identification No.)

 

640 Lee Road, Suite 200

Wayne, PA 19087

 

 

 

(Address of principal executive offices) (Zip code)

 

2015 Equity Incentive Plan

 

 

 

(Full title of the plan)

 

Neal Walker

President and Chief Executive Officer

Aclaris Therapeutics, Inc.

640 Lee Road, Suite 200

Wayne, PA 19087

(484) 324-7933

_____________________________________

 

(Name and address of agent for service) (Telephone number, including area code, of agent for service)

Copies to:

   
Brian F. Leaf
Mark Ballantyne
Cooley LLP
11951 Freedom Drive
Reston, VA 20190-5640
(703) 456-8000

Kamil Ali-Jackson
Chief Legal Officer
Aclaris Therapeutics, Inc.
640 Lee Road, Suite 200

Wayne, PA 19087
(484) 324-7933

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

               
Large accelerated filer   ¨     Accelerated filer   ¨
Non-accelerated filer   x     Smaller reporting company   x
          Emerging growth company   ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

 

 

 

 

 

CALCULATION OF REGISTRATION FEE

 

Title of Securities to be Registered   Amount to be
Registered (1)
  Proposed Maximum
Offering Price
Per Share (2)
    Proposed Maximum
Aggregate Offering
Price (2)
    Amount of
Registration Fee
 
Common Stock, par value $0.00001 per share   1,804,372 shares   $ 24.02     $ 43,341,015.44     $ 4,728.51  

 

(1)    Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s Common Stock that become issuable under the 2015 Equity Incentive Plan (the “2015 EIP”) set forth herein by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of the Registrant’s Common Stock.

 

(2)    Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) promulgated under the Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate offering price are calculated using the average of the high and low prices of the Registrant’s Common Stock as reported on the Nasdaq Global Select Market on May 4, 2021. The chart below details the calculations of the registration fee:

 

Securities   Number of
Shares
    Offering Price Per
Share (2)
    Aggregate
Offering Price
 
Additional shares reserved for future grant under the 2015 EIP     1,804,372     $ 24.02 (2)   $ 43,341,015.44  
Proposed Maximum Aggregate Offering Price                   $ 43,341,015.44  
Registration Fee                   $ 4,728.51  

 

2 

 

 

EXPLANATORY NOTE

 

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,804,372 shares of Common Stock of Aclaris Therapeutics, Inc. to be issued pursuant to the 2015 EIP.

 

3 

 

 

PART II

 

ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

 

The contents of the earlier registration statement relating to the 2015 EIP, previously filed with the Securities and Exchange Commission on October 15, 2015 (File No. 333-207434) are incorporated herein by reference and made a part of this Registration Statement.

 

4 

 

 

ITEM 8. EXHIBITS

 

Exhibit
Number
  Description
4.1 (1)   Amended and Restated Certificate of Incorporation of the Registrant.
4.2 (2)   Amended and Restated Bylaws of the Registrant.
4.3 (3)   Specimen stock certificate evidencing shares of the Registrant’s Common Stock.
4.4 (4)   2015 Equity Incentive Plan.
4.5 (5)   Form of Stock Option Grant Notice and Stock Option Agreement under 2015 Equity Incentive Plan.
4.6 (6)   Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under 2015 Equity Incentive Plan.
4.7 (7)   Form of Performance Stock Option Grant Notice and Stock Option Agreement used in connection with the 2015 Equity Incentive Plan.
4.8 (8)   Form of Performance Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement used in connection with the 2015 Equity Incentive Plan.
5.1     Opinion of Cooley LLP.
23.1     Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.
23.2     Consent of Cooley LLP (included in Exhibit 5.1).
24.1     Power of Attorney (included on the signature page of this Form S-8).

 

 

 

(1) Previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the Commission on October 13, 2015, and incorporated by reference herein.

 

(2) Previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the Commission on June 24, 2020, and incorporated by reference herein.

 

(3) Previously filed as Exhibit 4.1 to Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-206437), filed with the Commission on September 25, 2015, and incorporated by reference herein.

 

(4) Previously filed as Exhibit 4.6 to the Registrant’s Registration Statement on Form S-8 (File No. 333-207434), filed with the Commission on October 15, 2015, and incorporated by reference herein.

 

(5) Previously filed as Exhibit 10.10 to Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-206437), filed with the Commission on September 25, 2015, and incorporated by reference herein.

 

(6) Previously filed as Exhibit 10.11 to Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-206437), filed with the Commission on September 25, 2015, and incorporated by reference herein.

 

(7) Previously filed as Exhibit 10.11 to the Registrant’s Annual Report on Form 10-K (File No. 001-37581), filed with the Commission on March 18, 2019, and incorporated by reference herein.

 

(8) Previously filed as Exhibit 10.12 to the Registrant’s Annual Report on Form 10-K (File No. 001-37581), filed with the Commission on March 18, 2019, and incorporated by reference herein.

 

 

 

5 

 

 

ITEM 9. UNDERTAKINGS

 

1. The undersigned registrant hereby undertakes:

 

(a)            To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

(i)                  To include any prospectus required by Section 10(a)(3) of the Securities Act;

 

(ii)                 To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

 

(iii)               To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

 

Provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

 

(b)            That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(c)            To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

2. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

3. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

6 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wayne, Commonwealth of Pennsylvania, on this 7th day of May, 2021.

 

  Aclaris Therapeutics, Inc.
   
  By: /s/ Neal Walker
    Neal Walker
    President and Chief Executive Officer

 

7 

 

 

POWER OF ATTORNEY

 

Know All Persons By These Presents, that each person whose signature appears below constitutes and appoints Neal Walker, Kamil Ali-Jackson and Frank Ruffo, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature   Title   Date
         

/s/ Neal Walker

 Neal Walker

 

President, Chief Executive Officer and Director

(Principal Executive Officer)

  May 7, 2021
         

/s/ Frank Ruffo

 Frank Ruffo

 

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

  May 7, 2021
         

/s/ Christopher Molineaux

Christopher Molineaux

  Chairman of the Board of Directors   May 7, 2021
         

/s/ Anand Mehra, M.D.

Anand Mehra, M.D.

  Director   May 7, 2021
         

/s/ William Humphries

 William Humphries

  Director   May 7, 2021
         

/s/ Andrew Powell

 Andrew Powell 

  Director   May 7, 2021
         

/s/ Andrew Schiff

 Andrew Schiff

  Director   May 7, 2021
         
/s/ Bryan Reasons   Director   May 7, 2021
Bryan Reasons      
         
/s/ Maxine Gowen   Director   May 7, 2021
Maxine Gowen      
         
/s/ Vincent Milano   Director   May 7, 2021
Vincent Milano      

 

8 

 

 

Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Aclaris Therapeutics Charts.
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Aclaris Therapeutics Charts.